Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
17.35
+0.23 (1.34%)
Sep 22, 2026, 1:28 PM EDT - Market open
Dyne Therapeutics Employees
Dyne Therapeutics had 289 employees as of June 30, 2026. The number of employees increased by 83 or 40.29% compared to the same quarter last year.
Employees
289
Change
83
Growth
40.29%
Revenue / Employee
n/a
Profits / Employee
-$1,797,249
Market Cap
3.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 289 | 83 | 40.29% |
| Mar 31, 2026 | 263 | 71 | 36.98% |
| Dec 31, 2025 | 258 | 67 | 35.08% |
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Zai Lab | 1,784 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
DYN News
- 4 days ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Dyne Therapeutics Transcript: 2026 Global Healthcare Conference - Transcripts
- 8 days ago - Dyne Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 11 days ago - Dyne Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 13 days ago - Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley - TheFly
- 13 days ago - Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital - TheFly
- 13 days ago - Dyne Therapeutics price target lowered to $26 from $30 at Baird - TheFly
- 13 days ago - Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan - TheFly